Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Harrisburg Wellness Reporter.
Press releases published on December 2, 2025
December 2, 2025
Caresify Home Care Expands Home Health Division to Deliver Skilled In-Home Clinical Care
Indeterminate
EIN Presswire
December 2, 2025
Cremstar Becomes the First to Offer 100% Green Aquamation Statewide in Both New Jersey and Pennsylvania
Indeterminate
EIN Presswire
December 2, 2025
Clene to Provide CNM-Au8® ALS Program Update
Indeterminate
GlobeNewswire
December 2, 2025
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Indeterminate
GlobeNewswire
December 2, 2025
Conflicting Guidance and Rapid Innovation Leave Physicians Seeking Clarity in Relapsed/Refractory Multiple Myeloma
Indeterminate
GlobeNewswire
December 2, 2025
Publication relating to transparency notifications
Indeterminate
GlobeNewswire
December 2, 2025
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Indeterminate
GlobeNewswire
December 2, 2025
Verano Awarded Conditional License to Commence Vertical Cannabis Operations in Texas
Indeterminate
GlobeNewswire
December 2, 2025
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Indeterminate
GlobeNewswire
December 2, 2025
FISHER HOUSE FOUNDATION RECEIVES “FOUR STARS” FOR 22nd YEAR FROM CHARITY NAVIGATOR, A+ FROM CHARITY WATCH
Indeterminate
GlobeNewswire
December 2, 2025
Caresify Home Care Introduces Blue Zone–Inspired Care Framework After Studying Longevity Practices Across the Globe
Indeterminate
EIN Presswire
December 2, 2025
Hawai’i Cancer Care and American Oncology Network Open New Kahului Clinic
Indeterminate
GlobeNewswire
December 2, 2025
AMPS Achieves HITRUST e1 Certification, Solidifying Commitment to Data Security in Healthcare
Indeterminate
GlobeNewswire
December 2, 2025
Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases
Indeterminate
GlobeNewswire
December 2, 2025
Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
Indeterminate
GlobeNewswire